Zhang ZL, Peng MS, Chen ZM, Long T, Wang LS, Xu ZL. Effect of aluminum phosphate gel on prevention of early rebleeding after ligation of esophageal variceal hemorrhage. World J Gastrointest Surg 2021; 13(12): 1651-1659 [PMID: 35070070 DOI: 10.4240/wjgs.v13.i12.1651]
Corresponding Author of This Article
Zheng-Lei Xu, MD, Associate Professor, Chief Doctor, The Second Clinical Medical College of Jinan University, No. 1017 Dongmen North Road, Shenzhen 518000, Guangdong Province, China. 78249073@qq.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Zhu-Liang Zhang, Min-Si Peng, Ze-Ming Chen, Ting Long, Li-Sheng Wang, Zheng-Lei Xu, The Second Clinical Medical College of Jinan University, Shenzhen 518000, Guangdong Province, China
Zhu-Liang Zhang, Min-Si Peng, Ze-Ming Chen, Li-Sheng Wang, Zheng-Lei Xu, Department of Gastroenterology, Shenzhen People's Hospital, Shenzhen 518020, Guangdong Province, China
Ting Long, Department of Pathology, Shenzhen People’s Hospital, Shenzhen 518020, Guangdong Province, China
Author contributions: Xu ZL conceived the idea for the study; Zhang ZL, Peng MS, Chen ZM, Long T, and Xu ZL collected the case data and drafted the manuscript; Wang LS reviewed and revised the manuscript.
Supported byNatural Science Foundation of Guangdong Province of China, No. 2018A0303130278.
Institutional review board statement: The study was reviewed and approved by the ethics committee of Shenzhen People’s Hospital.
Informed consent statement: This study has received informed consent from all patients.
Conflict-of-interest statement: The authors declare no conflict of interest for this article.
Data sharing statement: Dataset available from the corresponding author at 78249073@qq.com.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Zheng-Lei Xu, MD, Associate Professor, Chief Doctor, The Second Clinical Medical College of Jinan University, No. 1017 Dongmen North Road, Shenzhen 518000, Guangdong Province, China. 78249073@qq.com
Received: April 27, 2021 Peer-review started: April 27, 2021 First decision: July 14, 2021 Revised: July 14, 2021 Accepted: November 14, 2021 Article in press: November 14, 2021 Published online: December 27, 2021 Processing time: 240 Days and 10.3 Hours
ARTICLE HIGHLIGHTS
Research background
Endoscopic variceal ligation (EVL) is a common treatment for esophageal variceal bleeding (EVB), but early rebleeding may occur after endoscopic therapy. And most patients are released from the hospital by the time they bleed again, which can be life-threatening.
Research motivation
How to reduce the early rebleeding after EVL is very important. Oral medication is accessible and convenient for patients. Therefore, we wanted to study oral drugs to reduce the rate of early rebleeding after EVL.
Research objectives
This study aimed to investigate oral medications to reduce early rebleeding after EVL. It was found that the combination of proton pump inhibitor (PPI) and aluminum phosphate gel (APG) could significantly reduce the incidence of early rebleeding. This oral treatment regimen is clinically worthwhile.
Research methods
The patients were divided into two groups. One group was treated with oral PPI after EVL. The other group was treated with oral PPI combined with APG. A retrospective study was conducted to compare and analyze the therapeutic effects of the two groups of patients.
Research results
We found that PPI combined with APG therapy could significantly reduce the rate of early rebleeding after EVL, and reduce the incidence of chest pain after EVL. But this is a retrospective study and it would be nice to do a prospective multicenter study.
Research conclusions
To prevent early rebleeding after EVL, the combination of PPI and APG can be considered.
Research perspectives
Oral medications are used to reduce the risk of postoperative rebleeding in EVL patients.
